Is NeueHealth Stock a Good Investment?
NeueHealth Investment Advice | NEUE |
- Examine NeueHealth's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NeueHealth's leadership team and their track record. Good management can help NeueHealth navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact NeueHealth's business and its evolving consumer preferences.
- Compare NeueHealth's performance and market position to its competitors. Analyze how NeueHealth is positioned in terms of product offerings, innovation, and market share.
- Check if NeueHealth pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NeueHealth's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NeueHealth stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NeueHealth is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine NeueHealth Stock
Researching NeueHealth's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 64.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. NeueHealth had 1:80 split on the 22nd of May 2023.
To determine if NeueHealth is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeueHealth's research are outlined below:
| NeueHealth generated a negative expected return over the last 90 days | |
| NeueHealth has high historical volatility and very poor performance | |
| NeueHealth has a very high chance of going through financial distress in the upcoming years | |
| NeueHealth was previously known as Bright Health Group and was traded on New York Stock Exchange under the symbol BHG. | |
| The company reported the previous year's revenue of 1.16 B. Net Loss for the year was (1.15 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeueHealth generates negative cash flow from operations | |
| NeueHealth has a frail financial position based on the latest SEC disclosures | |
| About 64.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: SIGEP WORLD CHRISTMAS OBSERVATORY BY IEG NEUE IDEEN UND TRENDS FR DIE FESTLICHE TAFEL |
NeueHealth uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeueHealth. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeueHealth's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact NeueHealth's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises NeueHealth's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-04 | 2022-03-31 | -0.2418 | -0.32 | -0.0782 | 32 | ||
2021-08-03 | 2021-06-30 | -0.1598 | -0.28 | -0.1202 | 75 | ||
2022-08-10 | 2022-06-30 | -0.3225 | -0.45 | -0.1275 | 39 | ||
2023-03-01 | 2022-12-31 | -0.49 | -0.34 | 0.15 | 30 | ||
2022-11-09 | 2022-09-30 | -0.35 | -0.5 | -0.15 | 42 | ||
2023-05-09 | 2023-03-31 | -0.1 | -0.3 | -0.2 | 200 | ||
2021-11-11 | 2021-09-30 | -0.146 | -0.48 | -0.334 | 228 | ||
2022-03-02 | 2021-12-31 | -0.4494 | -1.29 | -0.8406 | 187 |
NeueHealth's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.8 M.Market Cap |
|
NeueHealth's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (0.97) | |
| Return On Capital Employed | 3.48 | 3.65 | |
| Return On Assets | (0.94) | (0.89) | |
| Return On Equity | 3.35 | 3.52 |
Determining NeueHealth's profitability involves analyzing its financial statements and using various financial metrics to determine if NeueHealth is a good buy. For example, gross profit margin measures NeueHealth's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeueHealth's profitability and make more informed investment decisions.
Please note, the presentation of NeueHealth's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeueHealth's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NeueHealth's management manipulating its earnings.
Evaluate NeueHealth's management efficiency
NeueHealth has return on total asset (ROA) of (0.0358) % which means that it has lost $0.0358 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8326) %, meaning that it created substantial loss on money invested by shareholders. NeueHealth's management efficiency ratios could be used to measure how well NeueHealth manages its routine affairs as well as how well it operates its assets and liabilities. At present, NeueHealth's Return On Equity is projected to increase slightly based on the last few years of reporting. At present, NeueHealth's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.32, whereas Non Current Assets Total are forecasted to decline to about 129.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (32.01) | (30.41) | |
| Tangible Book Value Per Share | (43.73) | (41.55) | |
| Enterprise Value Over EBITDA | (0.62) | (0.65) | |
| Price Book Value Ratio | (0.19) | (0.20) | |
| Enterprise Value Multiple | (0.62) | (0.65) | |
| Price Fair Value | (0.19) | (0.20) | |
| Enterprise Value | 1.4 B | 1.3 B |
NeueHealth benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 0.855 |
Basic technical analysis of NeueHealth Stock
As of the 28th of November, NeueHealth secures the Risk Adjusted Performance of 0.0019, mean deviation of 2.34, and Standard Deviation of 3.2. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeueHealth, as well as the relationship between them. Please verify NeueHealth market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if NeueHealth is priced some-what accurately, providing market reflects its recent price of 4.77 per share. Given that NeueHealth has information ratio of (0.05), we recommend you to check NeueHealth's last-minute market performance to make sure the company can sustain itself at a future point.NeueHealth's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeueHealth insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeueHealth's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeueHealth insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeueHealth's Outstanding Corporate Bonds
NeueHealth issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeueHealth uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeueHealth bonds can be classified according to their maturity, which is the date when NeueHealth has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| BHF 175 13 JAN 25 Corp BondUS10921U2H03 | View | |
| BHF 155 24 MAY 26 Corp BondUS10921U2C16 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| BRIGHTHOUSE FINL INC Corp BondUS10922NAF06 | View |
Understand NeueHealth's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NeueHealth's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0019 | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (13,350) | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.26 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 16.93 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 6.28 | |||
| Skewness | 0.2789 | |||
| Kurtosis | 1.27 |
| Risk Adjusted Performance | 0.0019 | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (13,350) | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.26 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 16.93 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 6.28 | |||
| Skewness | 0.2789 | |||
| Kurtosis | 1.27 |
Consider NeueHealth's intraday indicators
NeueHealth intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeueHealth stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
NeueHealth Corporate Filings
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 13th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
NeueHealth Stock media impact
Far too much social signal, news, headlines, and media speculation about NeueHealth that are available to investors today. That information is available publicly through NeueHealth media outlets and privately through word of mouth or via NeueHealth internal channels. However, regardless of the origin, that massive amount of NeueHealth data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeueHealth news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeueHealth relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeueHealth's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeueHealth alpha.
NeueHealth Corporate Management
| Jeff Craig | General Secretary | Profile | |
| Jeffrey Scherman | Chief Officer | Profile | |
| Jay Matushak | Chief Officer | Profile | |
| Tomas Orozco | Executive Care | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeueHealth. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade NeueHealth Stock refer to our How to Trade NeueHealth Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeueHealth. If investors know NeueHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeueHealth listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 145.939 | Quarterly Revenue Growth 0.286 | Return On Assets (0.04) | Return On Equity (1.83) |
The market value of NeueHealth is measured differently than its book value, which is the value of NeueHealth that is recorded on the company's balance sheet. Investors also form their own opinion of NeueHealth's value that differs from its market value or its book value, called intrinsic value, which is NeueHealth's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeueHealth's market value can be influenced by many factors that don't directly affect NeueHealth's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between NeueHealth's value and its price, as these two are different measures arrived at by various means. Investors typically determine if NeueHealth is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeueHealth's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.